Related Experiment Videos
Etanercept: in ankylosing spondylitis
Paul L McCormack1, Keri Wellington
1Adis International Inc., Yardley, Pennsylvania 19067, USA. demail@adis.co.nz
Summary
Etanercept effectively treats ankylosing spondylitis by blocking tumor necrosis factor-alpha (TNFα). This biologic therapy significantly reduces disease activity and improves quality of life in patients.
Area of Science:
- Immunology
- Rheumatology
- Pharmacology
Background:
- Ankylosing spondylitis is a chronic inflammatory condition.
- Tumor necrosis factor-alpha (TNFα) plays a key role in its pathogenesis.
- Existing treatments have limitations.
Purpose of the Study:
- To evaluate the efficacy and safety of etanercept in treating active ankylosing spondylitis.
- To assess the impact of etanercept on disease activity and quality of life.
Main Methods:
- Randomized, double-blind, placebo-controlled trials were conducted.
- Patients received subcutaneous etanercept (25mg twice weekly) or placebo for 6-24 weeks.
- Disease activity was assessed using ASAS 20 response criteria.
Main Results:
- Etanercept significantly reduced disease activity compared to placebo (57% vs. 22% response rate at 24 weeks).
- Significant improvements were observed in physical functioning, pain, vitality, and social functioning.
- Etanercept was generally well-tolerated with a favorable safety profile.
Conclusions:
- Subcutaneous etanercept is an effective treatment for active ankylosing spondylitis.
- Etanercept improves both disease activity and health-related quality of life.
- The therapy demonstrates a good safety and tolerability profile.